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from receiving best practice treatment every year3. Our 
vision for Nano-X is to provide a cost-effective solution for 
radiotherapy treatment by moving much of the complexity 
from the hardware to the software. Our aim is to produce a 
commercially viable system within three years. 
Materials and Methods: The Nano-X collaboration has utilised 
patient rotation technology to significantly reduce the 
complexity, and thus cost, of radiotherapy. Patient rotation 
technology allows the patient to be mechanically moved 
during treatment, in contrast to a conventional device which 
moves the linac, typically weighing about 3T, around a fixed 
patient position. This allows the use of a static linac and thus 
also reduces the size and cost of the bunker. The Nano-X 
includes a 6MV linac with MLC, MV panel and a novel kV cone-
beam imaging system. The integrated imaging systems allow 
for real-time and adaptive image guided therapy which will 
alleviate the requirements of pre-treatment patient 
alignment reducing the on-site staffing burden. 
Results: The Nano-X prototype is currently under 
construction by LinaTech Medical Technologies Ltd and is due 
for completion and installation at Nelune Comprehensive 
Cancer Centre (NCCC) in 2015, with a planned commercial 
product available in 3 years. The initial estimated cost of a 
commercial Nano-X is around 10% of the cost of a 
conventional RT machine, with bunker costs reduced by up to 
67%2. 
Conclusions: With the low-cost and design that is specifically 
tailored towards LIMCs as well as rural and remote regions 
the Nano-X represents a solution to RT availability 
worldwide. The Nano-X prototype is currently under 
construction and will be installed at NCCC in 2015. 
Discussions are underway to determine the first LMIC 
treatment site. 
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Purpose/Objective: Alterations in metabolism seem to 
influence initiation of malignancy as well as recurrence. 
However the effect of diabetes, as one of the most common 
endocrine disorders, and metformin therapy on glioblastoma 
(GBM), remain understudied. Our aim is to examine the 
influence of diabetes and metformin on progression and 
survival in GBM patients.  
Materials and Methods: 270 patients with primary 
glioblastoma underwent radiation therapy between 2007 and 
2011 at the XXX. We assessed clinical records as well as 
pretherapeutic and follow up MR-imaging. 33 patients (12.2 
%) were identified with a pretherapeutic history of diabetes, 
treated with metformin in 14 cases (42.4 %). Survival and 
correlations were calculated using the t-test, log-rank 
analysis and univariate cox proportional hazards ratio. 
Results: Diabetes was associated with significant decreased 
overall survival rates (p = .047) in GBM patients in the 
prognostic favorable subgroup without corticosteroid 
therapy. Furthermore persistent mild - (p < .001) and 
persistent excessive hyperglycemia (p < .001) correlated with 
decreased survival. Interestingly, diabetic patients with 
metformin therapy showed a prolonged progression-free 
interval (p = .037). Recurrence patterns were not affected by 
diabetes or metformin therapy. 
Conclusions: We could show an adverse relationship between 
diabetes and survival in GBM patients. Furthermore our 
clinical findings suggest that metformin therapy prolongs the 
progression-free survival in GBM patients with diabetes. 
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Purpose/Objective: The prognosis in patients with high grade 
glioma remains poor, and the use of dose escalation beyond 
60 Gy using three-dimensional conformal radiotherapy (RT) or 
intensity-modulated radiotherapy (IMRT) has not lead to a 
survival benefit. Previous experimental and clinical studies 
indicated that hyperbaric oxygen (HBO) therapy could 
enhance an antitumor effect of RT. A few clinical studies 
indicated that HBO therapy immediately before conventional 
RT was safe and seemed to be effective in patients with high 
grade glioma. We conducted the combination therapy of 
chemoradiotherapy (CRT) using IMRT boosts in combination 
with HBO therapy. The purpose of this study was to evaluate 
the feasibility and efficacy of the combination therapy.  
